Communicating the Value of Pharmacodynamic Modelling in Drug ...
Communicating the Value of Pharmacodynamic Modelling in Drug ...
Communicating the Value of Pharmacodynamic Modelling in Drug ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Q2: What is <strong>the</strong> probability that, <strong>in</strong> comb<strong>in</strong>ation with a<br />
stat<strong>in</strong>, gemcabene is cl<strong>in</strong>ically superior to ezetimibe?<br />
LDL % Change<br />
from Basel<strong>in</strong>e<br />
1 Plot<br />
Treatments<br />
LDL % change frm basel<strong>in</strong>e vs Atorvastat<strong>in</strong><br />
1 Plot<br />
Treatments<br />
LDL % change frm basel<strong>in</strong>e vs Atorvastat<strong>in</strong><br />
.<br />
20<br />
.<br />
20<br />
CI1027 0<br />
CI1027 900<br />
LDL % change frm basel<strong>in</strong>e<br />
.<br />
0<br />
0<br />
-20 Gemcabene Atorvastat<strong>in</strong> comb<strong>in</strong>ation will -20 not provide<br />
alone<br />
alone<br />
Ezetimibe 0<br />
-40superior LDL-C lower<strong>in</strong>g relative . -40<br />
to ezetimibe<br />
Ezetimibe 10<br />
-60<br />
LDL % change frm basel<strong>in</strong>e<br />
-60<br />
Atorvastat<strong>in</strong><br />
.<br />
-80<br />
0 20 40 60 80<br />
Atorvastat<strong>in</strong><br />
.<br />
-80<br />
0 20 40 60 80<br />
+ Gemcabene 900 mg + Ezetimibe 10 mg<br />
Atorvastat<strong>in</strong><br />
Atorvastat<strong>in</strong><br />
dose (mg)<br />
slide 39<br />
30 May 2008, ARCS<br />
© Pharsight Corporation All Rights Reserved
Change language